Literature DB >> 15765258

The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats.

Sanders A McDougall1, Rita M Hernandez, Carmela M Reichel, Cristal M Farley.   

Abstract

RATIONALE: In adult rats, the partial D(2)-like agonist terguride acts as an antagonist at normosensitive D(2)-like post-synaptic receptors, while it acts as an agonist at the same receptors during states of low dopaminergic tone.
OBJECTIVE: The purpose of the present study was to determine whether partial D(2)-like agonists exhibit both antagonistic and agonistic actions during the preweanling period.
METHODS: In experiments 1 and 2 (examining the agonistic actions of terguride), preweanling rats were either given an escalating regimen of amphetamine to induce a state of amphetamine withdrawal or pretreated with the tyrosine hydroxylase inhibitor AMPT. Distance traveled was measured after rats were injected with saline, terguride (0.4-1.6 mg/kg), or the full D(2)-like receptor agonist NPA (0.01 mg/kg). In experiment 3 (examining the antagonistic actions of terguride), preweanling rats were pretreated with terguride 30 min before they were tested with saline, NPA (0.05 mg/kg), or amphetamine (1.5 mg/kg).
RESULTS: NPA had an exaggerated locomotor activating effect when tested under conditions of amphetamine withdrawal, while the partial D(2)-like agonist did not enhance distance traveled under any circumstance. Similarly, NPA increased and terguride did not affect the distance-traveled scores of AMPT-pretreated rats. In experiment 3, terguride pretreatment significantly reduced the distance traveled of amphetamine-treated and NPA-treated rats.
CONCLUSIONS: The behavioral evidence indicates that, during the preweanling period, terguride antagonizes D(2)-like post-synaptic receptors in a state of high dopaminergic tone; however, there is no evidence that terguride is capable of stimulating D(2)-like post-synaptic receptors during states of low dopaminergic tone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15765258     DOI: 10.1007/s00213-004-2033-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  48 in total

1.  Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.

Authors:  Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; Jean-Paul Nicolas; Frédéric De Ceuninck; Jean-A Boutin; Mark J Millan
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

2.  Ontogeny of dopamine D1 receptors in rat forebrain: a quantitative autoradiographic study.

Authors:  L C Murrin; W Y Zeng
Journal:  Brain Res Dev Brain Res       Date:  1990-12-01

3.  Discriminative stimulus effects of cocaine in squirrel monkeys: lack of antagonism by the dopamine D2 partial agonists terguride, SDZ 208-911, and SDZ 208-912.

Authors:  R D Spealman
Journal:  Pharmacol Biochem Behav       Date:  1995-08       Impact factor: 3.533

4.  Development of striatal dopaminergic function. I. Pre- and postnatal development of mRNAs and binding sites for striatal D1 (D1a) and D2 (D2a) receptors.

Authors:  A B Jung; J P Bennett
Journal:  Brain Res Dev Brain Res       Date:  1996-07-20

5.  Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.

Authors:  K Svensson; A Ekman; M F Piercey; W E Hoffmann; J T Lum; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-09       Impact factor: 3.000

6.  A dopamine partial agonist and antagonist block amphetamine self-administration in a progressive ratio schedule.

Authors:  E Izzo; C Orsini; G F Koob; L Pulvirenti
Journal:  Pharmacol Biochem Behav       Date:  2001-04       Impact factor: 3.533

Review 7.  Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

8.  Relationship between receptor occupancy and response at striatal dopamine autoreceptors.

Authors:  E Meller; K Bohmaker; Y Namba; A J Friedhoff; M Goldstein
Journal:  Mol Pharmacol       Date:  1987-06       Impact factor: 4.436

9.  Effects of irreversible dopamine receptor inactivation on locomotor activity and grooming in the 17- and 90-day-old rat.

Authors:  S A McDougall; C A Crawford; A J Nonneman
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Depletion of catecholamines in the brain of rats differentially affects stimulation of locomotor activity by caffeine, D-amphetamine, and methylphenidate.

Authors:  I B Finn; P M Iuvone; S G Holtzman
Journal:  Neuropharmacology       Date:  1990-07       Impact factor: 5.250

View more
  4 in total

1.  Ontogenetic differences in sensitivity to LiCl- and amphetamine-induced taste avoidance in preweanling rats.

Authors:  Damián Alejandro Revillo; Norman E Spear; Carlos Arias
Journal:  Chem Senses       Date:  2011-03-28       Impact factor: 3.160

2.  The partial dopamine D2-like receptor agonist terguride functions as an agonist in preweanling rats after a 5-day reserpine regimen.

Authors:  Jennifer J Wacan; Carmela M Reichel; Cristal M Farley; Sanders A McDougall
Journal:  Psychopharmacology (Berl)       Date:  2006-01-31       Impact factor: 4.530

3.  Effects of dopamine and serotonin synthesis inhibitors on the ketamine-, d-amphetamine-, and cocaine-induced locomotor activity of preweanling and adolescent rats: sex differences.

Authors:  Sanders A McDougall; Jasmine W Rios; Matthew G Apodaca; Ginny I Park; Nazaret R Montejano; Jordan A Taylor; Andrea E Moran; Jasmine A M Robinson; Timothy J Baum; Angie Teran; Cynthia A Crawford
Journal:  Behav Brain Res       Date:  2019-10-23       Impact factor: 3.332

4.  Development of a peptide targeting dopamine transporter to improve ADHD-like deficits.

Authors:  Terence K Y Lai; Ping Su; Hailong Zhang; Fang Liu
Journal:  Mol Brain       Date:  2018-11-09       Impact factor: 4.041

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.